講座・研究室 腎臓内科学講座【腎臓内科学】

教室紹介

    
腎臓内科への入局・大学院進学をお考えの方へ
当教室は1969年(昭和44年)の臓器別講座導入の際、大野丞二初代教授(現名誉教授)により誕生しました。2代目教授・小出輝教授(現名誉教授)のあとを引き継ぎ、現在は3代目教授・富野康日己教授のもと約80名の現役教室員とともにIgA腎症、糖尿病性腎症、本態性高血圧、腎不全等をテーマに、研究・臨床・教育にあたっています。
教室運営の理念は、まず心温まる医療・診療を実践しうる"良き臨床医"の育成を第一義とし、臨床に直結した研究を進め、その成果を患者さんにフィードバックしていくことです。当教室では、年配の者がもつ知識や技術を惜しみなく年下の者に与え、またその下へと伝えていくという良き伝統によって培われてきました。単に医学知識を深めるだけではなく、患者さんに対して "もし自分の身内であったならどのような対応ができるのか"を念頭に、なおかつ冷静な判断のもとに最善を尽くす"良き臨床医"としての姿勢も代々受け継がれてきました。

教室には野球チーム「ベアーズ」がありますが、"教室とは、1人1人がお互いに連携しながら各ポジションを守り、一丸となって攻守する野球チームのようなものだ"と思います。当教室では、優秀な女医さんも多くなりましたので、女子ボーリングチーム「ビューティーベアーズ」を作りました。これらのレジャーを通じても、当科のチーム医療が一層深まっていると思われます。
全国から患者さんが集まるような「患者さん本意の医療を行う腎臓内科」を目指す一方、研究面でもピンポイントの新知見を世界に発信し続けていきたいと考えています。

野球チーム「ベアーズ」

研究

基礎研究は、炎症性腎疾患グループ、代謝性腎疾患グループ、末期腎不全グループの3つのグループで構成されています。炎症性腎疾患グループには、さらにIgA腎症を主なテーマとする腎炎グループ、補体グループ、ポドサイトグループの各サブグループがあります。代謝性腎疾患グループは主に糖尿病腎症を、末期腎不全グループは主に腹膜透析をテーマとしています。
現在、慢性腎不全となり血液・腹膜透析を導入される患者は年間約3万人おり、この数は年々増えていく傾向にあります。末期腎不全の主な原因疾患である糖尿病腎症、また慢性腎炎の大半を占めるIgA腎症の発症・進展機序の一刻も早い解明が期待されています。私達臨床医の義務と考える基礎研究と臨床との相互のフィードバック(From Bench to Bedside, From Bedside to Bench)を念頭におき、これら疾患の解明のために分子生物学的手法を駆使し研究を行っています。現在の各グループの研究活動を簡単に紹介します。

炎症性腎疾患グループ

腎炎グループ
  1. IgA腎症グループ
    1. 病因・病態解明
      1. Mucosa Bone marrow axisへのアプローチ
        • 責任細胞の同定と局在
        • 粘膜免疫の関与(樹状細胞の役割、補体制御)
        • 細胞性免疫の関与(Th2 biasの発症への関与)
        • Mucosa Bone marrow間のtrafficking制御
        • ヒト扁桃における自然免疫の関与
        • 糖鎖異常IgA産生機序と粘膜・自然免疫の関与
      2. IgAの糸球体沈着後の動態と制御
        • 糖鎖異常IgAの沈着機序の動的解析
        • Mesangial pathwayと炎症惹起機転(リンパ流路の解析)
        • IgA受容体と炎症制御(in situおよびsystemicな治療応用のためのモデル開発)
      3. 発症・進展因子の遺伝子制御
        • grouped ddYマウスでの責任遺伝子解析
        • ヒトIgA腎症患者での確認(SNP)
    2. 診断・治療応用
      1. IgA腎症早期診断・活動性評価
        • 糖鎖異常IgAと特異的ペプチド解析(アラバマ大学共同研究)
        • Fcα/μシステムを用いた定量化
      2. 扁摘パルス治療基準作成
  2. 腎炎全般
    1. 糸球体腎炎の発症・進展における各種メディエーターの関与
      • レニン・アンジオテンシン系の関与
      • 虚血・酸化ストレスの関与とその制御(KIM-1、L-FABP)
      • IgA受容体による炎症制御
      • 心腎・脳腎連関
    2. 半月体形成性腎炎
      • モデルの作成(p-ANCAモデル、c-ANCAモデル)
      • 遺伝子制御(トランスポゾン)
      • 治療応用(Rho kinase inhibitor)
補体グループ
  1. 第三の補体活性化経路レクチン経路の臨床的意義
    1. レクチン経路活性化測定法の開発
    2. 腎炎におけるレクチン経路を介した発症・進展機序の解明
    3. 透析患者におけるレクチン経路の関与
  2. 補体から見た腎炎・ネフローゼ症候群の発症機序の検討
    1. 血中・尿中・腎組織上の補体および補体制御因子の解析
    2. 補体および補体制御因子の遺伝学的検討
  3. 補体からみた慢性腎不全、透析患者の病態解明
    1. 補体制御因子の遺伝子多型と機能異常
    2. 補体制御因子の糖化による機能異常
  4. 電子顕微鏡を用いた腎生検組織の検討
    1. 腎組織における補体および補体制御因子の局在
  5. 補体成分欠損患者の病態解明
    1. 遺伝性血管浮腫(C1-inhibitor欠損)
ポドサイトグループ
  • ネフローゼ症候群・糸球体硬化(蛋白尿)の病態解明と新規治療薬の開発
  • ポドサイト障害の程度を測定する新規検査の開発

代謝性腎疾患グループ

糖尿病腎症の発症・進展機序の解明
  • 2型糖尿病腎症自然発症モデルであるKKマウスを用いたQTLマッピング
  • ヒト糖尿病腎症での候補遺伝子解析
  • 糖尿病腎症の進展に関与する終末糖化産物(AGE)を介した酸化・インスリン抵抗性の役割
  • モデルマウスを用いた各種治療薬(HMG-CoA、ARB、PPARγなど)の糖尿病腎症進展抑制に及ぼす効果の検討

末期腎不全グループ

腹膜透析領域 ―腹膜劣化の予防と障害腹膜修復の促進―
  • 残存腎機能が心臓機能に及ぼす影響の検討
  • 腹膜組織の血管網の障害(虚血状態)が腹膜組織に及ぼす影響の検討
  • 不死化中皮細胞株の樹立と不死化中皮細胞の障害腹膜移植による修復機転の変化の検討
  • 障害腹膜修復機転における骨髄由来幹細胞の関与に関する検討
  • 腹膜透析患者の腹膜組織障害の評価方法の検討
血液透析領域
  • 内シャントによる血行動態変化の心臓機能への影響の検討
腎不全領域
  • 腎不全モデルラットを用いた動脈硬化発症機転の検討

教育・医学部教育

現在、慢性腎不全となり血液・腹膜透析を導入される患者は年間約3万人おり、この数は年々増加傾向にある。我々は常に、臨床医の義務と考える基礎研究と臨床との相互のフィードバック(From Bench to Bedside, From Bedside to Bench)を念頭におき、これら疾患の解明のために分子生物学的手法を駆使し研究を行っている。なかでも、世界的に頻度の高い原発性糸球体腎炎で、特に日本で最も多いとされているIgA腎症の発症・進展機序の解明に関する研究を精力的に行っている。また、医療経済的にも深刻となっている透析医療において、透析療法導入の原因で最も頻度の高い糖尿病腎症の発症・進展因子の解明に関しても力を注いでいる。

研究内容の詳細はこちら

入局1年~5年目

後期研修が終了していない場合は、内科認定医資格を取得可能とするため、1年間必要とされる症例の研修を行う。この期間に、関連病院での研修を行うことができる。後期研修がすでに終了している場合は、各研究グループ[炎症性腎疾患(IgA腎症など)、代謝性腎疾患(糖尿病腎症など)、末期腎不全(主に腹膜透析)]に直接配属される。約4年間にわたり、分子生物学的手法などを駆使し、各研究グループの上級医の指導のもとで、世界に通ずる研究を行い論文にまとめる。また、国内(日本内科学会・日本腎臓学会・日本透析医学会・日本糖尿病学会など)・国外(国際腎臓学会・アジア太平洋腎臓学会・アメリカ腎臓学会・アメリカ糖尿病学会など)の学会に積極的に参加し、研究結果を世界に発信する。4年で大学院を卒業し単位(甲種)を取得するが、優秀な研究では3年でも取得可能である。

6年~9年目

研究を引き続き行う場合には、国内・国外留学を行う。また、これまで研究で行ってきた経験をいかし、臨床医として活躍する場合には、附属病院あるいは関連病院において腎臓病のスペシャリストとして、外来・入院患者の診療にあたる。その間に、腎臓内科専門医や透析専門医を取得する。

9年・10年目以降

自分の専門性にあった部署に勤務し、その専門性をさらに高めるとともに、指導医師として研修医および若手医師、医学生の教育・指導にあたる。

教授

経歴
平成2年順天堂大学医学部卒業
専門分野
IgA腎症、高血圧

鈴木 祐介(すずき ゆうすけ)

医学部・大学院医学研究科:教授
順天堂医院:腎・高血圧内科

y_suzuki_211011

経歴
昭和57年順天堂大学医学部卒業
専門分野
腎臓病

船曳 和彦ふなびき かずひこ

医学部・大学院医学研究科:教授
順天堂江東高齢者医療センター:腎・高血圧内科 科長

funabiki

経歴
平成6年順天堂大学医学部卒業
専門分野
腎不全、透析療法

井尾 浩章(いお ひろあきろ)

医学部・大学院医学研究科:教授
練馬病院:腎・高血圧内科

経歴
平成8年順天堂大学医学部卒業
専門分野
IgA腎症

鈴木 仁(すずき ひとし)

医学部・大学院医学研究科:教授
浦安病院:腎・高血圧内科

先任准教授

経歴
平成4年山形大学医学部卒業
専門分野
ネフローゼ症候群

清水 芳男(しみず よしお)

医学部:先任准教授
大学院医学研究科:准教授
静岡病院:腎臓内科 科長

shimizu

経歴
平成6年順天堂大学医学部卒業
専門分野
糖尿病性腎臓病、腎臓病(全般)

合田 朋仁(ごうだ ともひと)

医学部:先任准教授
大学院医学研究科:准教授
順天堂医院:腎・高血圧内科 医局長

准教授

経歴
平成7年久留米大学医学部卒業
専門分野
腎臓病(全般)、高血圧

上田 誠二(うえだ せいじ)

医学部・大学院医学研究科:准教授
順天堂医院:腎・高血圧内科 外来医長

経歴
平成9年順天堂大学医学部卒業
専門分野
腎臓病(全般)

髙原 久嗣(たかはら ひさつぐ)

医学部・大学院医学研究科:准教授
浦安病院:腎・高血圧内科

経歴
平成10年順天堂大学医学部卒業
専門分野
慢性腎臓病、腎代替療法

中田 純一郎(なかた じゅんいちろう)

医学部・大学院医学研究科:准教授
順天堂医院:腎・高血圧内科

経歴
平成12年順天堂大学医学部卒業
専門分野
ネフローゼ症候群、電解質異常、多発性嚢胞腎、腎臓病(全般)

木原 正夫(きはら まさお)

医学部・大学院医学研究科:准教授
順天堂医院:腎・高血圧内科 病棟医長

経歴
平成12年順天堂大学医学部卒業
専門分野
遺伝性血管性浮腫、腎臓病(全般)

眞野 訓(まの さとし)

医学部・大学院医学研究科:准教授
順天堂医院:腎・高血圧内科
(臨床研究センターより出向)

経歴
平成12年順天堂大学医学部卒業
専門分野
IgA腎症、腎臓病(全般)

山田 耕嗣(やまだ こうし)

医学部・大学院医学研究科:准教授
順天堂医院:腎・高血圧内科

経歴
平成13年順天堂大学医学部卒業
専門分野
糖尿病性腎臓病、腎臓病(全般)

村越 真紀(むらこし まき)

医学部・大学院医学研究科:准教授
順天堂医院:腎・高血圧内科

経歴
平成14年順天堂大学医学部卒業
専門分野
慢性腎臓病、腎代替療法

井下 博之(いのした ひろゆき)

医学部・大学院医学研究科:准教授
順天堂江東高齢者医療センター:腎・高血圧内科

英文論文 2018
  • Suzuki H, Yasutake J, Makita Y, Tanbo Y, Yamasaki K, Sofue T, Kano T, Suzuki Y.: IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1-oriented pathogenesis. Kidney Int. 2018; 93: 700-705.
  • Ohsawa I, Honda D, Hisada A, Inoshita H, Onda-Tsueshita K, Mano S, Sato N, Nakamura Y, Shimizu T, Gotoh H, Goto Y, Suzuki Y, Tomino Y.: Clinical Features of Hereditary and Mast Cell-mediated Angioedema Focusing on the Differential Diagnosis in Japanese Patients. Intern Med. 2018; 57:319-324.
  • Hamada C, Nakamoto H, Suzuki Y.: Morphologic characteristics of macroscopic peritoneal finding in patients with peritoneal dialysis. J Artif Organs. 2018; 21:102-109.
  • Placzek WJ, Yanagawa H, Makita Y, Renfrow MB, Julian BA, Rizk DV, Suzuki Y, Novak J, Suzuki H.: Serum galactose-deficient-IgA1 and IgG autoantibodies correlate in patients with IgA nephropathy. PLOS ONE. 2018; 13: e0190967.
  • Taguchi K, Yamagishi S, Yokoro M, Ito S, Kodama G, Kaida Y, Nakayama Y, Ando R, Yamada-Obara N, Asanuma K, Matsui T, Higashimoto Y, Brooks CR, Ueda S, Okuda S, Fukami K.: RAGE-aptamer attenuates deoxycorticosterone acetate/salt-induced renal injury in mice. Sci Rep. 2018; 8: 2686.
  • Shimizu M, Furuichi K, Toyama T, Funamoto T, Kitajima S, Hara A, Ogawa D, Koya D, Ikeda K, Koshino Y, Kurokawa Y, Abe H, Mori K, Nakayama M, Konishi Y, Samejima KI, Matsui M, Yamauchi H, Gohda T, Fukami K, Nagata D, Yamazaki H, Yuzawa Y, Suzuki Y, Fujimoto S, Maruyama S, Kato S, Naito T, Yoshimura K, Yokoyama H, Wada T.: Decline in estimated glomerular filtration rate is associated with risk of end-stage renal disease in type 2 diabetes with macroalbuminuria: an observational study from JDNCS. Clin Exp Nephrol. 2018; 22(2):377-387.
  • Asao R, Seki T, Takagi M, Yamada H, Kodama F, Hosoe-Nagai Y, Tanaka E, Trejo JAO, Yamamoto-Nonaka K, Sasaki Y, Hidaka T, Ueno T, Yanagita M, Suzuki Y, Tomino Y, Asanuma K. Rac1 in podocytes promotes glomerular repair and limits the formation of sclerosis. Sci Rep. 2018; 8(1):5061.
  • Gohda T, Nishizaki Y, Murakoshi M, Nojiri S, Yanagisawa N, Shibata T, Yamashita M, Tanaka K, Yamashita Y, Suzuki Y, Kamei N. Clinical predictive biomarkers for normoalbuminuric diabetic kidney disease. Diabetes Res Clin Pract. 2018; 3(141):62-68.
  • Yamamoto R, Imai E, Maruyama S, Yokoyama H, Sugiyama H, Nitta K, Tsukamoto T, Uchida S, Takeda A, Sato T, Wada T, Hayashi H, Akai Y, Fukunaga M, Tsuruya K, Masutani K, Konta T, Shoji T, Hiramatsu T, Goto S, Tamai H, Nishio S, Shirasaki A, Nagai K, Yamagata K, Hasegawa H, Yasuda H, Ichida S, Naruse T, Fukami K, Nishino T, Sobajima H, Tanaka S, Akahori T, Ito T, Yoshio T, Katafuchi R, Fujimoto S, Okada H, Ishimura E, Kazama JJ, Hiromura K, Mimura T, Suzuki S, Saka Y, Sofue T, Suzuki Y, Shibagaki Y, Kitagawa K, Morozumi K, Fujita Y, Mizutani M, Shigematsu T, Kashihara N, Sato H, Matsuo S, Narita I, Isaka Y. Regional variations in immunosuppressive therapy in patients with primary nephrotic syndrome: the Japan nephrotic syndrome cohort study. Clin Exp Nephrol. 018 ; 22 (6) : 1266 - 1280.
  • Honda D, Ohsawa I, Shimizu Y, Maiguma M, Hidaka T, Suzuki H, Io H, Mano S, Takahara H, Rinno H, Tomino Y, Suzuki Y. Suffocation due to Acute Airway Edema in a Patient with Hereditary Angioedema Highlighted the Need for Urgent Improvements in Treatment Availability in Japan. Intern Med. 2018 ; 57 (21) : 3193 - 3197.
  • Kaifu K, Ueda S, Nakamura N, Matsui T, Yamada-Obara N, Ando R, Kaida Y, Nakata M, Matsukuma-Toyonaga M, Higashimoto Y, Fukami K, Suzuki Y, Okuda S, Yamagishi SI. Advanced glycation end products evoke inflammatory reactions in proximal tubular cells via autocrine production of dipeptidyl peptidase-4. Microvasc Res. 120 : 90-93.
  • Kubo A, Shirato I, Hidaka T, Takagi M, Sasaki Y, Asanuma K, Ishidoh K, Suzuki Y. Expression of Cathepsin L and Its Intrinsic Inhibitors in Glomeruli of Rats With Puromycin Aminonucleoside Nephrosis. J Histochem Cytochem. 2018 ; 66(12) : 863 - 877.
  • Ikeda M, Terawaki H, Kanda E, Furuya M, Tanno Y, Nakao M, Maruyama Y, Maeda M, Higuchi C, Sakurada T, Kaneko T, Io H, Hashimoto K, Ueda A, Hirano K, Washida N, Yoshida H, Yoshikawa K, Taniyama Y, Harada K, Matsuo N, Okido I, Yokoo T. Interventional nephrology: current status and clinical impact in Japan. Clin Exp Nephrol. 22(2):437-447.
  • Suzuki H. Can Biomarkets Help in the Diagnosis and Management of IgAN?. Kidney Diseases. 4:145-194.
  • Suzuki Y. B Cells in IgAN and the Rationale for B Cell Directed Therapies in IgAN. Kidney Diseases. 4:145-194.
  • Io H, Suzuki Y. Strategy for Prevention of Left Ventricular Remodeling in Predialysis and Dialysis Patients. Contrib Nephrol. 196:13-21.
  • Honda D, Ohsawa I, Shimizu Y, Maiguma M, Hidaka T, Suzuki H, Io H, Mano S, Takahara H, Rinno H, Tomino Y, Suzuki Y. Suffocation due to Acute Airway Edema in a Patient with Hereditary Angioedema Highlighted the Need for Urgent Improvements in Treatment Availability in Japan. Intern Med. 1;57(21):3193-3197.
  • Thaha M, Empitu MA, Kadariswantiningsih IN, Nugroho CW, Hasanatulidhhiyah N, Rasyid H, EI Hakim Z, Suryansyah MM, Alda RR, Alsagaff MY, Amin M, Santoso D, Suzuki Y. Anthropometry-based Body Fat Percentage Predicts High hs-CRP in Chronic Kidney Disease Patients. Indones Biomed J. 10(2):184-191.
  • Sato D, Gohda T, Kihara M, Kanaguchi Y, Kobayashi T, Mano S, Sasaki Y, Nohara N, Murakoshi M, Nakata J, Suzuki H, Ueda S, Horikoshi S, Suzuki Y. Effect of Zinc Acetate Dihydrate (NobelzinR) Tretement on Anemia and Taste Disorders in Patients with Chronic Kidney Disease with Hypozincemia. Acta Medica Okayama. 72;(5): 535-538.
  • Kamei N, Yamashita M, Nishizaki Y, Yanagisawa N, Nojiri S, Tanaka K, Yamashita Y, Shibata T, Murakoshi M, Suzuki Y, Gohda T. Association between circulating tumor necrosis factor-related biomarkers and estimated glomerular filtration rate in type 2 diabetes. Sci Rep. 8; (1) : 15302.
  • Inoue M, Yamamotoya T, Nakatsu Y, Ueda K, Inoue Y, Matsunaga Y, Sakoda H, Fujishiro M, Ono H, Morii K, Sasaki K, Masaki T, Suzuki Y, Asano T, Kushiyama K. The Xanthine Oxidase Inhibitor Febuxostat Suppresses the Progression of IgA Nephropathy, Possibly via Its Anti-Inflammatory and Anti-Fibrotic Effects in the gddY Mouse Model. Int. J. Mol. Sci. 19(12). pii: E3967.
  • Suzuki H, Suzuki Y. Murine Models of Human IgA Nephropathy. Semin Nephrol. ; 38 (5) : 513 - 520.
  • Takahashi K, Ueda K, Kobayashi T, Nishiyama A, Fujisawa T, Sugaya T, Shiota S, Takahashi K, Gohda T, Horikoshi S, Suzuki Y. Chronic intermittent hypoxia-madiated renal sympathetic nerve activation in hypertension and cardiovascular disease. Sci Rep. 8(1):17926.
  • Yamasaki K, Suzuki H, Yasutake J, Yamasaki Y, Suzuki Y. Galactose-Deficient IgA1-Specific Antibody Recognizes GalNAc-Modified Unique Epitope on Hinge Region of IgA1. Monoclon Antib Immunodiagn Immunother. 37(6):252-256.
英文原著 2017
  • Wakabayashi K, Io H, Nakata J, Nakamoto H, Sato M, Sasaki Y, Shimizu Y, Horikoshi S, Tomino Y, Suzuki Y: Effects of Cardiac Function with Postoperative Arteriovenous Fistula Blood Flow in Patients with Hemodialysis. Blood Purification. 2017; 44: 24-29
  • Gohda T, Maruyama S, Kamei N, Yamaguchi S, ShibataT, Murakoshi M, Horikoshi S, Tomino Y, Ohsawa I, Gotoh H, Nojiri S, Suzuki Y: Circulating TNF Receptors 1and 2 Predict Mortality in Patients with End-stage Renal Disease Undergoing Dialysis. Sci Rep. 2017; 7:43520
  • Murakoshi M, Gohda T, Sonoda Y, Suzuki H, Tomino Y, Horikoshi S, Suzuki Y: Effect of Tonsillectomy with Steroid Pulse Therapy on Circulating Tumor Necrosis Factor Receptors 1 and 2 in IgA Nephropathy. Clin Exp Nephrol. 2017; 21(102): 1-7
  • Berthoux F, Suzuki H, Mohey H, Maillard N, Mariat C, Novak J, Julian BA: Prognostic Value of Serum Biomarkers of Autoimmunity for Recurrence of IgA Nephropathy after Kidney Transplantation. J Am Soc Nephrol. 2017; 28(6): 1943-1950
  • Atikemu K, Suzuki Y, Otsuji M, Horikoshi S, Tomino Y: Influence of Estrogen on the Progression of Kindney Injury in Murine IgA Nephropathy. Juntendo Medical Journal 2017. 2017; 63(3): 178-185
  • Kanda R, Io H, Nakata J, Makita Y, Sasaki Y, Matsumoto M, Wakabayashi K, Tomino Y, Suzuki Y: Evaluation of Long-Term Combination Therapy With Peritoneal Dialysis and Hemodialysis. Ther Apher Dial. 2017: 21(2):180-184
  • Muto M, Manfroi B, Suzuki H, Joh K, Nagai M, Wakui S, Righini C, Maiguma M, Izui S, Tomino Y, Huard B, Suzuki Y: Toll-like Receptor 9 Stimulation lnduces Aberrant Expression of a Proliferation-lnducing Ligand by Tonsillar Germinal Center B Cell in IgA Nephropathy. J Am Soc Nephrol. 2017; 28(4):1227-1238
  • Kiryluk K, Li Y, Moldoveanu Z, Suzuki H, Reily C, Hou P, Xie J, Mladkova N, Prakash S, Fischman C, Shapiro S, LeDesma RA, Bradbury D, Ionita-Laza I, Eitner F, Rauen T, Maillard N, Berthoux F, Floege J, Chen N, Zhang H, Scolari F, Wyatt RJ, Julian BA, Gharavi AG, Novak J: GWAS for serum galactose-deficient IgA1 implicates critical genes of the O-glycosylation pathway. PLoS Genet. 2017; 10: e1006609,
  • Yokoro M, Nakayama Y, Yamagishi S. I., Ando R, Sugiyama M, Ito S, Yano J, Taguchi K., Kaida Y, Saigusa D, Kimoto M, Abe T, Ueda S, Fukami K: Asymmetric Dimethylarginine Contributes to the Impaired Response to Erythropoietin in CKD-Anemia. J Am Soc Nephrol. 2017; 28(9): 2671-2681
  • Hara K, Hamada C, Wakabayashi K, Kanda R, Kaneko K, Horikoshi S, Tomino Y, Suzuki Y: Scavenging of reactive oxygen species by astaxanthin inhibits epithelial-mesenchymal transition in high glucose-stimulated mesothelial cells. PLOS ONE. 2017; 12(9): e0184332
  • Sannohe T, Ohnuma T, Takeuchi M, Tani E, Miki Y, Takeda M, Katsuta N, Takebayashi Y, Nakamura T, Nishimon S, Kimoto A, Higashiyama R, Shibata N. Gohda T, Suzuki Y, Yamagishi S. I, Tomino Y, Arai H: High doses of antipsychotic polypharmacy are related to an increase in serum levels of pentosidine in patients with schizophrenia. 2017; 76: 42-48
  • Nishimon S, Ohnuma T, Takebayashi Y, Katsuta N, Takeda M, Nakamura T, Sannohe T, Higashiyama R, Kimoto A, Shibata N, Gohda T, Suzuki Y, Yamagishi S. I, Tomino Y, Arai H: High serum soluble tumor necrosis factor receptor 1 predicts poor treatment response in acute-stage schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2017; 76: 145-154
  • Jardine MJ, Kasiske B, Adu D, Alrukhaimi M, Ashuntantang GE, Basnet S, Chailimpamontree W, Craig JC, O’Donoghue DJ, Perkovic V, Powe NR, Roberts CJ, Suzuki Y, Tanaka T, Uhlig K: Closing the gap between evidence and practice in chronic kidney disease. Kidney International Supplements. 2017; 7: 114-121
  • Sasaki Y, Hidaka T, Ueno T, Akiba-Takagi M, Oliva Trejo JA, Seki T, Nagai-Hosoe Y, Tanaka E, Horikoshi S, Tomino Y, Suzuki Y, Asanuma K: Sorting Nexin 9 facilitates podocin endocytosis in the injured podocyte. Sci Rep. 2017; 7;7:43921
  • Hosoe-Nagai Y, Hidaka T, Sonoda A, Sasaki Y, Yamamoto-Nonaka K, Seki T, Asao R, Tanaka E, Trejo JAO, Kodama F, Takagi M, Tada N, Ueno T, Nishinakamura R, Tomino Y, Asanuma K: Re-expression of Sall1 in podocytes protects against adriamycin-induced nephrosis. LABORATORY INVESTIGATION. 2017; 97(11);1306-1320
  • Taga Y, Tanaka K, Hamada C, Kusubata M, Ogawa-Goto K, Hattori S: Hydroxyhomocitrulline Is a Collagen-Specific Carbamylation Mark that Affects Cross-link Formation. CELL CHEMICAL BIOLOGY. 2017; 24(10): 1276-+
  • Honda D, Ohsawa I, Sato N, Inoshita H, Mano S, Tomino Y, Suzuki Y: Diminished capacity of opsonization and immune complex solubilization, and detection of anti-C1q antibodies in sera from patients with hereditary angioedema. ALLERGOLOGY INTERNATIONAL. 2017; 66(4): 603-609
  • Pollock C, Zuk A, Anders HJ, Ganji MR, Johnson DW, Kasiske B, Langham RG, Pecoits R, Remuzzi G, Rossert J, Suzuki Y, Tanaka T, Walker R, Yang CW, Bonventre JV: The establishment and validation of novel therapeutic targets to retard progression of chronic kidney disease. KIDNEY INTERNATIONAL SUPPLEMENTS. 2017; 7(2): 130-137
  • Murakoshi M, Gohda T, Sonoda Y, Suzuki H, Tomino Y, Horikoshi S, Suzuki Y: Effect of tonsillectomy with steroid pulse therapy on circulating tumor necrosis factor receptors 1 and 2 in IgA nephropathy. CLINICAL AND EXPERIMENTAL NEPHROLOGY. 2017, 21(6): 1068-1074
  • Kawanishi K, Honda K, Hamada, C: Recommendations for pathological diagnosis on biopsy samples from peritoneal dialysis patients. PLEURA AND PERITONEUM. 2017; 2(1): 3-15
  • Fukami K, Yamagishi S, Kaifu K, Matsui T, Kaida Y, Ueda S, Takeuchi M, Asanuma K, Okuda S: Telmisartan inhibits AGE-induced podocyte damage and detachment (vol 88, pg 79, 2013). MICROVASCULAR RESEARCH. 2017; 110: 65
  • Ohsawa I, Honda D, Hisada A, Inoshita H, Onda-Tsueshita K, Mano S, Sato N, Nakamura Y, Shimizu T, Gotoh H, Goto Y, Suzuki Y, Tomino Y: Clinical Features of Hereditary and Mast Cell-mediated Angioedema Focusing on the Differential Diagnosis in Japanese Patients. Intern Med. 2017; 8624-16
  • Watanabe H, Goto S, Mori H, Higashi K, Hosomichi K, Aizawa N, Takahashi N, Tsuchida M, Suzuki Y, Yamada T, Horii A, Inoue I, Kurokawa K, Narita: Comprehensive microbiome analysis of tonsillar crypts in IgA nephropathy. NEPHROLOGY DIALYSIS TRANSPLANTATION. 2017; 32(23):2072-2079
英文原著 2016
  • Pesce F, Diciolla M, Binetti G, Naso D, Ostuni VC, Di Noia T, Vagane AM, Bjorneklett R, Suzuki H, Tomino Y, Di Sciascio E, Schena FP: Clinical decision support system for end-stage kidney disease risk estimation in IgA nephropathy patients. Nephrol Dial Transplant, 31, 1: 80-86, 2016
  • Yamamoto-Nonaka K, Koike M , Asanuma K, Takagi M, Juan Alejandro Oliva Trejo, Seki T, Hidaka T, Ichimura K, Sakai T, Tada N, Ueno T, Uchiyama Y, Tomino Y: Cathepsin D in Podocytes Is Important in the Pathogenesis of Proteinuria and CKD. J Am Soc Nephrol, 27, 9: 2685-2700, 2016
  • Nohara N, Io H, Matsumoto M, Furukawa M, Okumura K, Nakata J, Shimizu Y, Horikoshi S, Tomino Y: Predictive factors associated with increased progression to dialysis in early chronic kidney disease (stage 1-3) patients. Clinical and Experimental Nephrology, 20, 5: 740-747, 2016
  • Kamijo S, Nunomura S, Ra C, Kanaguchi Y, Suzuki Y, Ogawa H, Okumura K, Takai T: Innate basophil IL-4 responses against allergens, endotoxin, and cytokines require the Fc receptor gamma-chain. J Allergy Clin Immun, 137, 5: 1613-1615, 2016
  • Arai S, Kitada K, Yamazaki T, Takai R, Zhang XZ, Tsugawa Y, Sugisawa R, Matsumoto A, Mori M, Yoshihara Y, Doi K, Maehara N, Kusunoki S, Takahata A, Noiri E, Suzuki Y, Yahagi N, Nishiyama A, Gunaratnam L, Takano T, Miyazaki T: Apoptosis inhibitor of macrophage protein (AIM/CD5L) enhances intraluminal debris clearance and ameliorates acute kidney injury in mice. Nat Med, 22, 2: 183-193, 2016
  • Nakata J, Io H, Watanabe T, Sasaki Y, Makita Y, Aoki T, Yanagawa H, Kanda R, Tomino Y: Impact of preoperative ultrasonography findings on the patency rate of vascular access in Japanese hemodialysis patients. SpringerPlus, 5: 462, 2016
  • Huang ZQ, Raska M, Stewart TJ, Reily C, King RG, Crossman DK, Crowley MR, Hargett A, Zhang Z, Suzuki H, Hall S, Wyatt RJ, Julian BA, Renfrow MB, Gharavi AG, Novak J: Somatic Mutations Modulate Autoantibodies against Galactose-Deficient IgA1 in IgA Nephropathy. J Am Soc Nephrol, 27, 11: 3278-3284, 2016
  • Kato TS, Nakamura H, Murata M, Kuroda K, Suzuki H, Yokoyama Y, Shimada A, Matsushita S, Yamamoto T, Amano A: The effect of tolvaptan on renal excretion of electrolytes and urea nitrogen in patients undergoing coronary artery bypass surgery. BMC Cardiovasc Disord, 16: 181, 2016
  • Suzuki H, Allegri L, Suzuki Y, Hall S, Moldoveanu Z, Wyatt RJ, Novak J, Julian BA: Galactose-Deficient IgA1 as a Candidate Urinary Polypeptide Marker of IgA Nephropathy? Dis Markers,7806438 , 2016
  • Maruyama S, Gohda T, Suzuki Y, Suzuki H, Sonoda Y, Ichikawa S, Li Z, Murakoshi M, Horikoshi S, Tomino Y: Beneficial effects of tonsillectomy plus steroid pulse therapy on inflammatory and tubular markers in patients with IgA nephropathy. Kidney Res Clin Pract, 35, 4: 233-236, 2016
  • Idei M, Tabe Y, Hamada C, Miyake K, Takemura H, Io H, Wakita M, Horii T, Tomino Y, Ohsaka A, Miida T: Pancreatic lipase activity in overnight effluent predicts high transport status in peritoneal dialysis patients. Clinica Chimica Acta, 462: 65-70, 2016
  • Tawada M, Ito Y, Hamada C, Honda K, Mizuno M, Suzuki Y, Sakata F, Terabayashi T, Matsukawa Y, Maruyama S, Imai E, Matsuo S, Takei Y: Vascular Endothelial Cell Injury Is an Important Factor in the Development of Encapsulating Peritoneal Sclerosis in Long-Term Peritoneal Dialysis Patients. PLoS One, 11, 4: e015464, 2016
  • Honda D, Ohsawa I, Inoshita H, Sato N, Mano S, Horikoshi S, Tomino Y: Activity of cleaving enzymes for bradykinin in sera from patients with hereditary angioedema. Immunobiology, 221, 10: 1136-1136, 2016
  • Ishijima M, Kaneko H, Hada S, Kinoshita M, Sadatsuki R, Liu LZ, Shimura Y, Arita H, Shiozawa J, Yusup A, Futami I, Sakamoto Y, Ishibashi M, Machida S, Naito H, Arikawa-Hirasawa E, Hamada C, Saita Y, Takazawa Y, Ikeda H, Okada Y, Kaneko K: Osteoarthritis as a Cause of Locomotive Syndrome: Its Influence on Functional Mobility and Activities of Daily Living. Clinical Reviews in Bone and Mineral Metabolism, 14, 2: 77-104, 2016
  • Takahata A, Kitada K, Nogi C, Arai S, Makita Y, Suzuki H, Nakata J, Horikoshi S, Miyazaki T, Suzuki Y: AMI(CD5L) Regulates Glomerular IgA deposition and its Phlogogenisity in IgA Nephropathyregulates the Glomerular IgA deposition and its phlogogenisity in IgA nephropathy. Nephrol Dial Transplant, 31: 101-102, 2016
  • Yamanaka T, Tamauchi H, Suzuki Y, Suzuki H, Horikoshi S , Terashima M, Iwabuchi K, Habu S, Okumura K, Tomino Y: Release from Th1-type immune tolerance in spleen and enhanced production of IL-5 in Peyer's patch by cholera toxin B induce the glomerular deposition of IgA. IMMUNOBIOLOGY, 221,4: 577-585, 2016
  • Yamada-Obara N, Yamagishi SI, Taguchi K, Kaida Y, Yokoro M, Nakayama Y, Ando R, Asanuma K, Matsui T, Ueda S, Okuda S, Fukami K: Maternal exposure to high-fat and high-fructose diet evokes hypoadiponectinemia and kidney injury in rat offspring. Clin Exp Nephrol, 20, 6: 853-861, 2016
  • Tsuprykov O, Ando R, Reichetzeder C, von Websky K, Antonenko V, Sharkovska Y, Chaykovska L, Rahnenfuhrer J, Hasan AA, Tammen H, Alter M, Klein T, Ueda S, Yamagishi S, Okuda S, Hocher B: The dipeptidyl peptidase inhibitor linagliptin and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats with 5/6 nephrectomy. Kidney Int, 89, 5: 1049-61, 2016
  • Taguchi K, Ueda S, Fukami K: Accurate estimation of protein/creatinine ratio on urine sample in CKD patients. Clin Exp Nephrol, 20, 3: 319-21, 2016
  • Matsuzaki K, Suzuki H, Kobayashi T, Shimizu Y, Tomino Y: Analysis of Predictive Factors for Deterioration of Renal Function in Chronic Kidney Disease Patients. J Nephrol Ther, 6, 2: 240, 2016
  • Watanabe H, Goto S, Mori H, Higashi K, Hosomichi K, Aizawa N, Takahashi N, Tsuchida M, Suzuki Y, Yamada T, Horii A, Inoue I, Kurokawa K, Narita I: Comprehensive microbiome analysis of tonsillar crypts in IgA nephropathy. Nephrol Dial Transplant. pii: gfw343, 2016.
英文論文 2015
  • Jeong KH, Asanuma K, Lydia A, Takagi M, Asao R, Kodama F, Asanuma E, Tomino Y: Combination therapy with telmisartan and oxacalcitriol suppresses the progression of murine adriamycin nephropathy. Nephron, 129:143-154,DOI: 10.1159/000369346, 2015
  • Stuchlova Horynova M, Vrablikova A, Stewart TJ, Takahashi K, Czernekova L, Yamada K, Suzuki H, Julian BA, Renfrow MB, Novak J, Raska M: N-Acetylgalactosaminide α2,6-sialyltransferase II is a candidate enzyme for sialylation of galactose-deficient IgA1, the key autoantigen in IgA nephropathy. Nephrol Dial Transplant, 30: 234-238, DOI: 10.1093/ndt/gfu308, 2015
  • Sasaki Y, Shimizu Y, Suzuki Y, Horikoshi S, Tomino Y: TWEAK/Fn14 system and crescent fo formation in IgA nephropathy. BMC Nephrol, 16:27, DOI: 10.1186/s12882-015-0022-8, 2015
  • Sonoda Y, Gohda T, Suzuki Y, Omote K, Ishizaka M, Matsuoka J, Tomino Y: Circulating TNF receptors 1 and 2 are associated with the severity of renal interstitial fibrosis in IgA nephropathy. PLoS One. 10(4): e0122212, DOI: 10.1371/journal.pone.0122212, 2015
  • Takeda M, Ohnuma T, Takeuchi M, Katsuta N, Maeshima H, Takebayashi Y, Higa M, Nakamura T, Nishimon S, Sannohe T, Hotta Y, HanzawaR,Higashiyama R, Shibata N, GohdaT,Suzuki Y, Yamagishi SI, Tomino Y, Arai H: Altered serum glyceraldehyde-derived advanced glycation end product (AGE) and soluble AGE receptor levels indicate carbonyl stress in patients with schizophrenia. NeurosciLett, 23: 51-55, DOI: 10.1016/j.neu1et.2015.03.002, 2015
  • Suzuki Y, Suzuki H, Yasutake J, Tomino Y: Paradigm shift in activity assessment of IgA nephropathy-optimizing the next generation of diagnostic and therapeutic maneuvers via glycan-targeting. Expert Opinion on Biological Therapy, 15: 583-93, DOI: 10.1517/14712598.2015.1006624, 2015
  • Novak J, Rizk D, Takahashi K, Zhang XW, Bian Q, Ueda H, Ueda Y, Reily C, Lai LY, Hao C, Novak L, Huang ZQ, Renfrow MB, Suzuki H, Julian BA: New Insights into the Pathogenesis of IgA Nephropathy. Kidney Dis, 1: 8-18, DOI: 10.1159/000382134, 2015
  • Fukuda H, Hidaka T, Takagi-Akiba M, Ichimura K, Oliva Trejo JA, Sasaki Y, Wang J, Sakai T, Asanuma K, Tomino Y: Podocin is translocated to cytoplasm in puromycin aminonucleoside nephrosis rats and in poor-prognosis patients with IgA nephropathy. Cell Tissue Res, 360: 391-400, DOI: 10.1007/s00441-014-2100-9, 2015
  • Ohsawa I, Honda D, Nagamachi S, Hisada A, Shimamoto M, Inoshita H, Mano S, Tomino Y: Clinical manifestations, diagnosis, and treatment of hereditary angioedema: survey data from 94 physicians in Japan. Ann Allergy Asthma Immunol, 114(6): 492-8, DOI: 10.1016/j.anai.2015.03.010, 2015
  • Suzuki Y, Yasutake J, Suzuki H, Hiura N, Yanagawa H, Makita Y, Kaneko E, Tomino Y: Novel lectin-independent approach to detect galactose-deficient IgA1 in IgA Nephropathy.(1st and 2nd authors are equally contributed to this work). Nephrol Dial Transplant, 30(8): 1315-1321, DOI: 10.1093/ndt/gfv221 2015
  • Yang Gyun K, Alvarez M, Suzuki H, Hirose S, Izui S, Tomino Y, Bertrand H, Suzuki Y: Pathogenic Role of a Proliferation-Inducing Ligand (APRIL) in Murine IgA Nephropathy. PLoS One, 10(9): e0137044, DOI: 10.1371/journal.pone.0137044, 2015
  • Hamada C, Honda K, Kawanishi K, Nakamoto H, Ito Y, Sakurada T, Tanno Y, Mizumasa T, Miyazaki M, Moriishi M, Nakayama M: Morphological characteristics in peritoneum in patients with neutral peritoneal dialysis solution. J Artif Organs, 18: 243-250, DOI: 10.1007/s10047-015-0822-4, 2015
  • Nishizawa Y, Mizuiri S, Yorioka N, Hamada C, Tomino Y: Determinants of coronary artery calcification in maintenance hemodialysis patients. J Artif Organs, 18(3): 251-256, DOI: 10.1007/s10047-015-0823-3, 2015
  • Liu C, Kanamaru Y, Watanabe T, Tada N, Horikoshi S, Suzuki Y, Zhihong L, Tomino Y: Targeted IgA Fc Receptor I (Fc alpha RI) Therapy in the Early Intervention and Treatment of Pristane Induced Lupus Nephritis in Mice. ClinExpImmunol, 181(3): 407-416, DOI: 10.1111/cei.12647, 2015
  • Yamahatsu A, Hamada C, Kaneko K,Io H, Nakata J, Tomino Y: Long-term outcome of encapsulating peritoneal sclerosis (EPS) patients in a single center. ClinExpNephrol, 19(5): 961-967, DOI: 10.1007/s10157-015-1081-7, 2015
  • Diciolla M, Binetti G, Noia TD, Pesce F, Schena FP, Vagane AN, Bjorneklett R, Suzuki H, Tomino Y, Naso D: Patient Classification and Outcome Prediction in IgA Nephropathy. Computers in Biology and Medicine, 66: 278-86, DOI: 10.1016/j.compbiomed.2015.09.003, 2015
  • Juan Wang, Asanuma K, Hidaka T,Sasaki Y, Tanaka E, Tgakagi-Akiba M, Juan Alejandro Oliva Trejo, Tomino Y: Newly Identified Molecules Related to Podocyte Injury Induced by Adriamycin. Juntendo Medical Journal, 61:34-40, 2015
  • Honda D, Tsueshita K, Ohsawa I, Miyashita T, Inoshita H, Shimamoto M, Horikoshi S, Morimoto S, Takasaki Y, Tomino Y: Clinical significance of renal interstitial fibrosis in patients with lupus nephritis. Juntendo Medical Journal, 61: 418-425, 2015
  • Hisada A, Shimamoto M, Ohsawa I, Honda D, Nagamachi S, Suzuki H, Inoshita H, Onda K, Mano S, Horikoshi S, Tomino Y: Clinical and histological characteristics in patients with non-IgA mesangioproliferative glomerulonephritis. Juntendo Medical Journal, 61:41-48, 2015
英文論文 2014
  • Adipose-derived mesenchymal stem cells transplantation facilitate experimental peritoneal fibrosis repair by suppressing epithelial-mesenchymal transition. Wakabayashi K, Hamada C, Kanda R, Nakano T, Io H, Horikoshi S, Tomino Y. J Nephrol. 2014
  • Impact of Body Mass Index on Progression of IgA Nephropathy Among Japanese Patients. Shimamoto M, Ohsawa I, Suzuki H, Hisada A, Nagamachi S, Honda D, Inoshita H, Shimizu Y, Horikoshi S, Tomino Y. J Clin Lab Anal. 2014
  • Serum under-O-glycosylated IgA1 level is not correlated with glomerular IgA deposition based upon heterogeneity in the composition of immune complexes in IgA nephropathy. Satake K, Shimizu Y, Sasaki Y, Yanagawa H, Suzuki H, Suzuki Y, Horikoshi S, Honda S, Shibuya K, Shibuya A, Tomino Y. BMC Nephrol. 2014 ;15:89
  • Fluctuation of serum C3 levels reflects disease activity and metabolic background in patients with IgA nephropathy: response to comment. Tomino Y. J Nephrol. 2014
  • Properdin has an ascendancy over factor H regulation in complement-mediated renal tubular damage. Nagamachi S, Ohsawa I, Suzuki H, Sato N, Inoshita H, Hisada A, Honda D, Shimamoto M, Shimizu Y, Horikoshi S, Tomino Y. BMC Nephrol. 2014 ;15:82
  • A panel of serum biomarkers differentiates IgA nephropathy from other renal diseases. Yanagawa H, Suzuki H, Suzuki Y, Kiryluk K, Gharavi AG, Matsuoka K, Makita Y, Julian BA, Novak J, Tomino Y. PLoS One. 2014 ;9:e98081
  • Effect of AST-120 on Endothelial Dysfunction in Adenine-Induced Uremic Rats. Inami Y, Hamada C, Seto T, Hotta Y, Aruga S, Inuma J, Azuma K, Io H, Kaneko K, Watada H, Tomino Y. Int J Nephrol. 2014 ;2014:164125
  • Uncoupling of glomerular IgA deposition and disease progression in alymphoplasia mice with IgA nephropathy. Aizawa M, Suzuki Y, Suzuki H, Pang H, Kihara M, Nakata J, Yamaji K, Horikoshi S, Tomino Y. PLoS One. 2014 ;9:e95365
  • Impacts of recombinant human erythropoietin treatment during predialysis periods on the progression of chronic kidney disease in a large-scale cohort study (Co-JET study). Akizawa T, Saito A, Gejyo F, Suzuki M, Nishizawa Y, Tomino Y, Tsubakihara Y, Akiba T, Hirakata H, Watanabe Y, Kawanishi H, Bessho M, Udagawa Y, Aoki K, Uemura Y, Ohashi Y; Co-JET Study Group. Ther Apher Dial. 2014 ;18:140-8
  • The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Shimamoto K, Ando K, Fujita T, Hasebe N, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ishimitsu T, Ito M, Ito S, Itoh H, Iwao H, Kai H, Kario K, Kashihara N, Kawano Y, Kim-Mitsuyama S, Kimura G, Kohara K, Komuro I, Kumagai H, et al. Hypertens Res. 2014 ;37:253-387
  • Transient increase in proteinuria, poly-ubiquitylated proteins and ER stress markers in podocyte-specific autophagy-deficient mice following unilateral nephrectomy. Oliva Trejo JA, Asanuma K, Kim EH, Takagi-Akiba M, Nonaka K, Hidaka T, Komatsu M, Tada N, Ueno T, Tomino Y. Biochem Biophys Res Commun. 2014 ;446:1190-6
  • Role of the TNF pathway in the progression of diabetic nephropathy in KK-A(y) mice. Omote K, Gohda T, Murakoshi M, Sasaki Y, Kazuno S, Fujimura T, Ishizaka M, Sonoda Y, Tomino Y. Am J Physiol Renal Physiol. 2014 ;306:F1335-47
  • A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin A nephropathy. Kawamura T, Yoshimura M, Miyazaki Y, Okamoto H, Kimura K, Hirano K, Matsushima M, Utsunomiya Y, Ogura M, Yokoo T, Okonogi H, Ishii T, Hamaguchi A, Ueda H, Furusu A, Horikoshi S, Suzuki Y, Shibata T, Yasuda T, Shirai S, Imasawa T, Kanozawa K, et al. Nephrol Dial Transplant. 2014 ;29:1546-53
  • Dietary zinc is a key environmental modifier in the progression of IgA nephropathy. Maiguma M, Suzuki Y, Suzuki H, Okazaki K, Aizawa M, Muto M, Tomino Y. PLoS One. 2014 ;9:e90558
  • Changes in nephritogenic serum galactose-deficient IgA1 in IgA nephropathy following tonsillectomy and steroid therapy. Nakata J, Suzuki Y, Suzuki H, Sato D, Kano T, Yanagawa H, Matsuzaki K, Horikoshi S, Novak J, Tomino Y. PLoS One. 2014 ;9:e89707
  • Low Hemoglobin Levels and Hypo-Responsiveness to Erythropoiesis-Stimulating Agent Associated With Poor Survival in Incident Japanese Hemodialysis Patients. Akizawa T, Saito A, Gejyo F, Suzuki M, Nishizawa Y, Tomino Y, Tsubakihara Y, Akiba T, Hirakata H, Watanabe Y, Kawanishi H, Bessho M, Udagawa Y, Aoki K, Uemura Y, Ohashi Y; JET Study Group. Ther Apher Dial. 2014
  • Notch2 activation ameliorates nephrosis. Tanaka E, Asanuma K, Kim E, Sasaki Y, Oliva Trejo JA, Seki T, Nonaka K, Asao R, Nagai-Hosoe Y, Akiba-Takagi M, Hidaka T, Takagi M, Koyanagi A, Mizutani S, Yagita H, Tomino Y. Nat Commun. 2014 ;5:3296
  • Suppressive effects of iron overloading on vascular calcification in uremic rats. Seto T, Hamada C, Tomino Y. J Nephrol. 2014 ;27:135-42
  • Serum levels of galactose-deficient immunoglobulin (Ig) A1 and related immune complex are associated with disease activity of IgA nephropathy. Suzuki Y, Matsuzaki K, Suzuki H, Okazaki K, Yanagawa H, Ieiri N, Sato M, Sato T, Taguma Y, Matsuoka J, Horikoshi S, Novak J, Hotta O, Tomino Y. Clin Exp Nephrol. 2014
  • The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study. Hosoya T, Kimura K, Itoh S, Inaba M, Uchida S, Tomino Y, Makino H, Matsuo S, Yamamoto T, Ohno I, Shibagaki Y, Iimuro S, Imai N, Kuwabara M, Hayakawa H. Trials. 2014 ;15:26
  • Cytokines alter IgA1 O-glycosylation by dysregulating C1GalT1 and ST6GalNAc-II enzymes. Suzuki H, Raska M, Yamada K, Moldoveanu Z, Julian BA, Wyatt RJ, Tomino Y, Gharavi AG, Novak J. J Biol Chem. 2014 ;289:5330-9
  • Accumulation of advanced glycation end products and beta 2-microglobulin in fibrotic thickening of the peritoneum in long-term peritoneal dialysis patients. Nakamoto H, Hamada C, Shimaoka T, Sekiguchi Y, Io H, Kaneko K, Horikoshi S, Tomino Y. J Artif Organs. 2014 ;17:60-8
  • Comparison between the fixation of peritoneal dialysis catheters to the peritoneal wall and the conventional placement technique: clinical experience and follow-up of a new implant technique for peritoneal dialysis catheters. Io H, Maeda K, Sekiguchi Y, Shimaoka T, Aruga S, Nakata J, Nakamoto H, Hotta Y, Koyanagi I, Inaba M, Kanda R, Nakano T, Wakabayashi K, Sasaki Y, Inuma J, Kaneko K, Hamada C, Fukui M, Tomino Y. Semin Dial. 2014 ;27:E42-7
  • Paracrine effects of transplanted mesothelial cells isolated from temperature-sensitive SV40 large T-antigen gene transgenic rats during peritoneal repair. Kanda R, Hamada C, Kaneko K, Nakano T, Wakabayashi K, Hara K, Io H, Horikoshi S, Tomino Y. Nephrol Dial Transplant. 2014 ;29:289-300
  • Overestimation of the risk of progression to end-stage renal disease in the poor prognosis' group according to the 2002 Japanese histological classification for immunoglobulin A nephropathy. Miyazaki Y, Kawamura T, Joh K, Okonogi H, Koike K, Utsunomiya Y, Ogura M, Matsushima M, Yoshimura M, Horikoshi S, Suzuki Y, Furusu A, Yasuda T, Shirai S, Shibata T, Endoh M, Hattori M, Akioka Y, Katafuti R, Hashiguchi A, Kimura K, Matsuo S, et al. Clin Exp Nephrol. 2014 ;18:475-80
  • Proposal of remission criteria for IgA nephropathy. Suzuki Y, Matsuzaki K, Suzuki H, Sakamoto N, Joh K, Kawamura T, Tomino Y, Matsuo S. Clin Exp Nephrol. 2014 ;18:481-6
  • Hyaline vascular type of unicentric Castleman's disease with proliferation of glomerular endothelial cells. Wakabayashi K, Asanuma K, Takeda Y, Arakawa A, Osawa I, Horikoshi S, Yao T, Tomino Y. Clin Nephrol. 2014 ;81:445-50
英文論文 2013
  • Significance of combined cyclosporine-prednisolone therapy and cyclosporine blood concentration monitoring for idiopathic membranous nephropathy with steroid-resistant nephrotic syndrome: a randomized controlled multicenter trial. Saito T, Iwano M, Matsumoto K, Mitarai T, Yokoyama H, Yorioka N, Nishi S, Yoshimura A, Sato H, Ogahara S, Shuto H, Kataoka Y, Ueda S, Koyama A, Maruyama S, Nangaku M, Imai E, Matsuo S, Tomino Y; The Refractory Nephrotic Syndrome Study Group. Clin Exp Nephrol. 2013
  • Disruption of Smad4 expression in T cells leads to IgA nephropathy-like manifestations. Inoshita H, Kim BG, Yamashita M, Choi SH, Tomino Y, Letterio JJ, Emancipator SN. PLoS One. 2013 ;8:e78736
  • A case of arteriovenous fistula after renal biopsy in an IgA nephropathy patient with macroscopic hematuria. Horikoshi S, Takahata A, Shiraishi A, Fukuda H, Ohsawa I, Kuwatsuru R, Tomino Y. Case Rep Nephrol Urol. 2013 ;3:64-8
  • Renoprotective effects of the L-/T-type calcium channel blocker benidipine in patients with hypertension. Tomino Y. Curr Hypertens Rev. 2013 ;9:108-14
  • Amelioration of angiotensin II-induced salt-sensitive hypertension by liver-type fatty acid-binding protein in proximal tubules. Osaki K, Suzuki Y, Sugaya T, Tanifuji C, Nishiyama A, Horikoshi S, Tomino Y. Hypertension. 2013 ;62:712-8
  • Transperitoneal calcium balance in anuric continuous ambulatory peritoneal dialysis and automated peritoneal dialysis patients. Hamada C, Tomino Y. Int J Nephrol. 2013 ;2013:863791
  • Leukocytosis and high hematocrit levels during abdominal attacks of hereditary angioedema. Ohsawa I, Nagamachi S, Suzuki H, Honda D, Sato N, Ohi H, Horikoshi S, Tomino Y. BMC Gastroenterol. 2013 ;13:123
  • Association of the cardioankle vascular index and ankle-brachial index with carotid artery intima media thickness in hemodialysis patients. Gohda T, Gotoh H, Gotoh Y, Yamaguchi S, Tomino Y. Int J Nephrol. 2013 ;2013:401525
  • Usefulness of HPLC assay for early detection of microalbuminuria in chronic kidney disease. Horikoshi S, Okuda M, Nishimura E, Ohsawa I, Suzuki Y, Shimizu Y, Hamada C, Tomino Y. J Clin Lab Anal. 2013 ;27:333-8
  • Effect of the Direct Renin Inhibitor Aliskiren on Urinary Albumin Excretion in Spontaneous Type 2 Diabetic KK-A (y) Mouse. Furukawa M, Gohda T, Hagiwara S, Tanimoto M, Horikoshi S, Funabiki K, Tomino Y. Int J Nephrol. 2013 ;2013:519130
  • Distribution of dimethylarginine-dimethylaminohydrolase-II (DDAH2) gene polymorphism in hemodialysis patients. Thaha M, Yusuf M, Empitu MA, Bakarman A, Tomino Y. Acta Med Indones. 2013 ;45:83-8
  • Pathogenesis and novel treatment from the mouse model of type 2 diabetic nephropathy. Furukawa M, Gohda T, Tanimoto M, Tomino Y. ScientificWorldJournal. 2013 ;2013:928197
  • Immunopathological predictors of prognosis in IgA nephropathy. Tomino Y. Contrib Nephrol. 2013 ;181:65-74
  • Fluctuation of serum C3 levels reflects disease activity and metabolic background in patients with IgA nephropathy. Suzuki H, Ohsawa I, Kodama F, Nakayama K, Ohtani A, Onda K, Nagamachi S, Kurusu A, Suzuki Y, Ohi H, Horikoshi S, Tomino Y. J Nephrol. 2013 ;26:708-15
  • Novel biomarkers for the progression of diabetic nephropathy: soluble TNF receptors. Gohda T, Tomino Y. Curr Diab Rep. 2013 ;13:560-6
  • Nationwide survey on current treatments for IgA nephropathy in Japan. Matsuzaki K, Suzuki Y, Nakata J, Sakamoto N, Horikoshi S, Kawamura T, Matsuo S, Tomino Y. Clin Exp Nephrol. 2013 ;17:827-33
  • Japan Renal Biopsy Registry and Japan Kidney Disease Registry: Committee Report for 2009 and 2010. Sugiyama H, Yokoyama H, Sato H, Saito T, Kohda Y, Nishi S, Tsuruya K, Kiyomoto H, Iida H, Sasaki T, Higuchi M, Hattori M, Oka K, Kagami S, Kawamura T, Takeda T, Hataya H, Fukasawa Y, Fukatsu A, Morozumi K, Yoshikawa N, Shimizu A, et al. Clin Exp Nephrol. 2013 ;17:155-73
  • Usefulness of change in estimated glomerular filtration rate as a predicting factor of progression of chronic kidney disease. Maeda K, Hamada C, Horikoshi S, Tomino Y. ISRN Nephrol. 2013 ;2013:351364
  • Translocation of dendrin to the podocyte nucleus in acute glomerular injury in patients with IgA nephropathy. Kodama F, Asanuma K, Takagi M, Hidaka T, Asanuma E, Fukuda H, Seki T, Takeda Y, Hosoe-Nagai Y, Asao R, Horikoshi S, Tomino Y. Nephrol Dial Transplant. 2013 ;28:1762-72
  • Experimental evidence of cell dissemination playing a role in pathogenesis of IgA nephropathy in multiple lymphoid organs. Nakata J, Suzuki Y, Suzuki H, Sato D, Kano T, Horikoshi S, Novak J, Tomino Y. Nephrol Dial Transplant. 2013 ;28:320-6
  • Predictive factors associated with change rates of LV hypertrophy and renal dysfunction in CKD patients. Okumura K, Io H, Matsumoto M, Seto T, Takagi M, Masuda A, Furukawa M, Nagahama L, Omote K, Hisada A, Hamada C, Horikoshi S, Tomino Y. Clin Nephrol. 2013 ;79:7-14
  • Pentraxin 3 as a new biomarker of peritoneal injury in peritoneal dialysis patients. Kanda R, Hamada C, Kaneko K, Nakano T, Wakabayashi K, Io H, Horikoshi S, Tomino Y. J Artif Organs. 2013 ;16:66-73
  • GFR estimation using standardized serum cystatin C in Japan. Horio M, Imai E, Yasuda Y, Watanabe T, Matsuo S; Collaborators Developing the Japanese Equation for Estimated GFR. Am J Kidney Dis. 2013 ;61:197-203
  • Extraglomerular C3 deposition and metabolic impacts in patients with IgA nephropathy. Ohsawa I, Kusaba G, Ishii M, Sato N, Inoshita H, Onda K, Hashimoto A, Nagamachi S, Suzuki H, Shimamoto M, Ohi H, Horikoshi S, Tomino Y. Nephrol Dial Transplant. 2013 ;28:1856-64
  • A histologic classification of IgA nephropathy for predicting long-term prognosis: emphasis on end-stage renal disease. Kawamura T, Joh K, Okonogi H, Koike K, Utsunomiya Y, Miyazaki Y, Matsushima M, Yoshimura M, Horikoshi S, Suzuki Y, Furusu A, Yasuda T, Shirai S, Shibata T, Endoh M, Hattori M, Katafuchi R, Hashiguchi A, Kimura K, Matsuo S, Tomino Y; Study Group Special IgA Nephropathy. J Nephrol. 2013 ;26:350-7
  • Acceleration of crescent formation by L1 retrotransposon in mouse BSA-induced nephritis. Mugitani N, Shimizu Y, Satake K, Suzuki Y, Horikoshi S, Tomino Y. J Nephrol. 2013 ;26:375-84
英文論文 2012
  • Lessons From the KK-Ay Mouse, a Spontaneous Animal Model for the Treatment of Human Type 2 Diabetic Nephropathy. Tomino Y. Nephrourol Mon. 2012 ;4:524-9
  • Campylobacter bacteremia in hemodialysis patients by eating raw meat - the importance of sanitary education. Shimizu Y, Ishii A, Takahata A, Kajiyama T, Yamahatsu A, Io H, Kurusu A, Hamada C, Horikoshi S, Tomino Y. Case Rep Nephrol Urol. 2012 ;2:145-51
  • Thyroid storm masked by hemodialysis and glucocorticoid therapy in a patient with rheumatoid arthritis. Sasaki Y, Shimizu Y, Nakata J, Kameda T, Muto M, Ohsawa I, IoH, Hamada C, Horikoshi S, Tomino Y. Case Rep Nephrol Urol. 2012 ;2:6-10
  • Predictors of prognosis in IgA nephropathy. Tomino Y. Kaohsiung J Med Sci. 2012 ;28:517-20
  • Renal disease in the elderly and the very elderly Japanese: analysis of the Japan Renal Biopsy Registry (J-RBR). Yokoyama H, Sugiyama H, SatoH, Taguchi T, Nagata M, Matsuo S, Makino H, Watanabe T, Saito T, Kiyohara Y, Nishi S, Iida H, Morozumi K, Fukatsu A, Sasaki T, Tsuruya K, Kohda Y, Higuchi M, Kiyomoto H, Goto S, Hattori M, Hataya H, et al. Clin Exp Nephrol. 2012 ;16:903-20
  • Guidelines for the use and interpretation of assays for monitoring autophagy. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, Ahn HJ, Ait-Mohamed O, Ait-Si-Ali S, Akematsu T, Akira S, Al-Younes HM, Al-Zeer MA, Albert ML, Albin RL, Alegre-Abarrategui J, Aleo MF, Alirezaei M, et al. Autophagy. 2012 ;8:445-544
  • Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy. Berthoux F, Suzuki H, Thibaudin L, Yanagawa H, Maillard N, Mariat C, Tomino Y, Julian BA, Novak J. J Am Soc Nephrol. 2012 ;23:1579-87
  • Effect of exercise on kidney function, oxidative stress, and inflammation in type 2 diabetic KK-A(y) mice. Ishikawa Y, Gohda T, Tanimoto M, Omote K, Furukawa M, Yamaguchi S, Murakoshi M, Hagiwara S, Horikoshi S, Funabiki K, Tomino Y. Exp Diabetes Res. 2012 ;2012:702948
  • Determination of severity of murine IgA nephropathy by glomerular complement activation by aberrantly glycosylated IgA and immune complexes. Hashimoto A, Suzuki Y, Suzuki H, Ohsawa I, Brown R, Hall S, Tanaka Y, Novak J, Ohi H, Tomino Y. Am J Pathol. 2012 ;181:1338-47
  • N-type calcium channel inhibition with cilnidipine elicits glomerular podocyte protection independent of sympathetic nerve inhibition. Lei B, Nakano D, Fujisawa Y, Liu Y, Hitomi H, Kobori H, Mori H, Masaki T, Asanuma K, Tomino Y, Nishiyama A. J Pharmacol Sci.2012 ;119:359-67
  • Urinary podocalyxin is an early marker for podocyte injury in patients with diabetes: establishment of a highly sensitive ELISA to detect urinary podocalyxin. Hara M, Yamagata K, Tomino Y, Saito A, Hirayama Y, Ogasawara S, Kurosawa H, Sekine S, Yan K. Diabetologia. 2012 ;55:2913-9
  • Risk of overestimation of kidney function using GFR-estimating equations in patients with low inulin clearance. Nakata J, Ohsawa I, Onda K, Tanimoto M, Kusaba G, Takeda Y, Kobayashi N, Asanuma K, Tanaka Y, Sato M, Inami Y, Suzuki H, Suzuki H, Masuda A, Nonaka K, Sasaki Y, Hisada A, Hamada C, Horikoshi S, Tomino Y. J Clin Lab Anal. 2012 ;26:248-53
  • Development of a model of early-onset IgA nephropathy. Okazaki K, Suzuki Y, Otsuji M, Suzuki H, Kihara M, Kajiyama T, Hashimoto A, Nishimura H, Brown R, Hall S, Novak J, Izui S, Hirose S, Tomino Y. J Am Soc Nephrol. 2012 ;23:1364-74
  • Successfully maintained hemodialysis for the treatment of chronic renal failure in a patient with Hallopeau-Siemens type recessive dystrophic epidermolysis bullosa. Iida H, Hasegawa T, Okuma K, Io H, Tomino Y, Ikeda S. J Dermatol. 2012;39:1088-9
  • Relationships between levels of urinary podocalyxin, number of urinary podocytes, and histologic injury in adult patients with IgA nephropathy. Asao R, Asanuma K, Kodama F, Akiba-Takagi M, Nagai-Hosoe Y, Seki T, Takeda Y, Ohsawa I, Mano S, Matsuoka K, Kurosawa H, Ogasawara S, Hirayama Y, Sekine S, Horikoshi S, Hara M, Tomino Y. Clin J Am Soc Nephrol. 2012 ;7:1385-93
  • Rivaroxaban vs. Warfarin in Japanese Patients With Atrial Fibrillation - The J-ROCKET AF Study - . Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, Izumi T, Koretsune Y, Kajikawa M, Kato M, Ueda H, Iwamoto K, Tajiri M; J-ROCKET AF study investigators. Circ J. 2012 ;76:2104-11
  • Differentiation of bone marrow-derived cells into regenerated mesothelial cells in peritoneal remodeling using a peritoneal fibrosis mouse model. Sekiguchi Y, Hamada C, Ro Y, Nakamoto H, Inaba M, Shimaoka T, Io H, Koyanagi I, Aruga S, Inuma J, Kaneko K, Hotta Y, Margetts PJ, Mochizuki H, Horikoshi S, Tomino Y. J Artif Organs. 2012 ;15:272-82
  • Pathological scenario with the mannose-binding lectin in patients with IgA nephropathy. Ohsawa I, Ishii M, Ohi H, Tomino Y. J Biomed Biotechnol. 2012 ;2012:476739
  • Experimental models of type-2 diabetic nephropathy. Tomino Y, Cooper ME, Kurtz TW, Shimizu Y. Exp Diabetes Res. 2012 ;2012:218917
  • A new screening method for proteinuria using Erythrosin B and an automated analyzer--rapid, sensitive and inexpensive determination. Horikoshi S, Higurashi A, Kaneko E, Yoshimura H, Ohsawa I, Suzuki Y, Hamada C, Tomino Y. Clin Chim Acta. 2012 ;413:1087-91
  • Significance of broad distribution of electron-dense deposits in patients with IgA nephropathy. Kusaba G, Ohsawa I, Ishii M, Inoshita H, Takagi M, Tanifuji C, Takahashi K, Nakamoto J, Yoshida M, Ohi H, Horikoshi S, Kurihara H, Tomino Y. Med Mol Morphol. 2012 ;45:29-34
  • Asymmetric dimethylarginine: a novel cardiovascular risk factor in end-stage renal disease. Alsagaff MY, Thaha M, Aminuddin M, Yogiarto RM, Yogiantoro M, Tomino Y. J Int Med Res. 2012 ;40:340-9
  • Significance of urinary full-length and ectodomain forms of megalin in patients with type 2 diabetes. Ogasawara S, Hosojima M, Kaseda R, Kabasawa H, Yamamoto-Kabasawa K, Kurosawa H, Sato H, Iino N, Takeda T, Suzuki Y, Narita I, Yamagata K, Tomino Y, Gejyo F, Hirayama Y, Sekine S, Saito A. Diabetes Care. 2012 ;35:1112-8
  • Risk factors associated with increased left ventricular mass index in chronic kidney disease patients evaluated using echocardiography. Matsumoto M, Io H, Furukawa M, Okumura K, Masuda A, Seto T, Takagi M, Sato M, Nagahama L, Omote K, Hisada A, Horikoshi S, Tomino Y. J Nephrol. 2012 ;25:794-801
  • Effects of acetate-free citrate dialysate on glycoxidation and lipid peroxidation products in hemodialysis patients. Masuda A, Hagiwara S, Tanimoto M, Kodama F, Okumura K, Nohara N, Matsumoto M, Maiguma M, Omote K, Io H, Kurusu A, Ohsawa I, Shimizu Y, Hamada C, Horikoshi S, Tomino Y. Nephron Extra. 2012 ;2:256-68
  • Effects of 22-oxa-calcitriol on podocyte injury in adriamycin-induced nephrosis. Lydia A, Asanuma K, Nonaka K, Takagi M, Jeong KH, Kodama F, Asao R, Asanuma E, Prodjosudjadi W, Tomino Y. Am J Nephrol. 2012 ;35:58-68
  • Rapamycin inhibits transforming growth factor β-induced peritoneal angiogenesis by blocking the secondary hypoxic response. Sekiguchi Y, Zhang J, Patterson S, Liu L, Hamada C, Tomino Y, Margetts PJ. J Cell Mol Med. 2012 ;16:1934-45
  • Relationship between preoperative radial artery and postoperative arteriovenous fistula blood flow in hemodialysis patients. Sato M, Io H, Tanimoto M, Shimizu Y, Fukui M, Hamada C, Horikoshi S, Tomino Y. J Nephrol. 2012 ;25:726-31
  • Doxorubicin-induced glomerulosclerosis with proteinuria in GFP-GABARAP transgenic mice. Takagi-Akiba M, Asanuma K, Tanida I, Tada N, Oliva Trejo JA, Nonaka K, Asanuma E, Kominami E, Ueno T, Tomino Y. Am J Physiol Renal Physiol. 2012 ;302:F380-9
  • Mechanisms and interventions in peritoneal fibrosis. Tomino Y. Clin Exp Nephrol. 2012 ;16:109-14
  • Severity-based treatment for Japanese patients with MPO-ANCA-associated vasculitis: the JMAAV study. Ozaki S, Atsumi T, Hayashi T, Ishizu A, Kobayashi S, Kumagai S, Kurihara Y, Kurokawa MS, Makino H, Nagafuchi H, Nakabayashi K, Nishimoto N, Suka M, Tomino Y, Yamada H, Yamagata K, Yoshida M, Yumura W, Amano K, Arimura Y, Hatta K, Ito S, et al. Mod Rheumatol. 2012 ;22:394-404
  • Tonsillar TLR9 expression and efficacy of tonsillectomy with steroid pulse therapy in IgA nephropathy patients. Sato D, Suzuki Y, Kano T, Suzuki H, Matsuoka J, Yokoi H, Horikoshi S, Ikeda K, Tomino Y. Nephrol Dial Transplant. 2012 ;27:1090-7
  • Identification of quantitative trait loci for diabetic nephropathy in KK-Ay/Ta mice. Aoki T, Kaneko S, Tanimoto M, Gohda T, Hagiwara S, Murakoshi M, Ishikawa Y, Furukawa M, Funabiki K, Horikoshi S, Tomino Y. J Nephrol. 2012 ;25:127-36

★平成30年度に後期研修ならびに大学院等進学を考えの先生方へ!

医学部卒業後2年または3年の卒後研修修了者または修了予定者で、当講座への入局あるいは大学院進学を希望される方の募集は、随時行っております。
遠慮なく下記へメールまたは電話でお問い合わせください。

医局長:合田 朋仁(ごうだ ともひと)
Tel 03-3813-3111(代表)
メールアドレス:jinnaika@juntendo.ac.jp

なお、後期研修の内容、講座所属後の進路(留学を含む)、認定医・専門医の取得、関連病院、講座の活動(臨床・研究部門)、その他休暇・部外活動(野球部:Bears・ボーリング部:Beauty Bears)・女性医師の勤務、など具体的な内容については、今秋、医局説明会の開催を予定しております。詳細が決まりましたらホームページに掲載いたします。